Trial
NCT02748564
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI)
Condition
Metastatic Melanoma
Intervention
Aldesleukin
Why stopped
Study Complete
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-03